You are here » Home » Companies » Company Overview » Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd.

BSE: 533573 Sector: Health care
NSE: APLLTD ISIN Code: INE901L01018
BSE LIVE 15:40 | 09 Dec 638.60 -0.55
(-0.09%)
OPEN

645.00

HIGH

646.00

LOW

635.35

NSE LIVE 15:48 | 09 Dec 637.55 -2.90
(-0.45%)
OPEN

647.00

HIGH

647.80

LOW

635.00

OPEN 645.00
PREVIOUS CLOSE 639.15
VOLUME 2480
52-Week high 727.25
52-Week low 514.35
P/E 20.60
Mkt Cap.(Rs cr) 12037.61
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 645.00
CLOSE 639.15
VOLUME 2480
52-Week high 727.25
52-Week low 514.35
P/E 20.60
Mkt Cap.(Rs cr) 12037.61
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Alembic Pharmaceuticals Ltd. (APLLTD) - Company History

Alembic Pharmaceuticals Ltd was incorporated on June 16 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in Pharamceulicals business. As per the scheme of arrangement the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date April 1 2010. In April 15 2011 the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 133515914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement the shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus the company became an associate of Alembic Ltd.In September 20 2011 the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange.During 2012 Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals Inc USA.During 2013 the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA.During 2014 the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A..During 2015 the companies associate signs exclusive agreement with Novartis.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard